Novartis Aktie

101,84 EUR -0,02 EUR -0,02 %

17:13:15

FSE

95,30 CHF +0,22 CHF +0,23 %

17:39:15

SWX

Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!

JETZT LOSLEGEN

Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handeln Smartphone

Marktkap.193,07 Mrd. EUR

KGV17,02Div. Rendite3,95%

WKN904278

ISINCH0012005267

SymbolNVSEF

Novartis Aktien News

Sortieren:Datum Meistgelesen

02.06.25GlobeNewswireNovartis Pluvicto™ demonstrates statistically significant and clinically meaningful rPFS benefit in patients with PSMA-positive metastatic hormone-sensitive prostate cancer

01.06.25GlobeNewswireNovartis Kisqali® reduces risk of recurrence in younger patients with early breast cancer in NATALEE subgroup analysis

27.05.25GlobeNewswireNovartis announces commencement of tender offer to acquire Regulus Therapeutics

WerbungNovartis-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero

15.05.25GlobeNewswireNew Novartis data at ASCO and EHA showcase momentum of pioneering portfolio with promising pipeline

30.04.25GlobeNewswireNovartis to acquire Regulus Therapeutics and farabursen, an investigational microRNA inhibitor to treat ADPKD, the most common genetic cause of renal failure

29.04.25GlobeNewswireNovartis setzt die starke Dynamik fort mit zweistelligem Umsatzwachstum, robusten Margensteigerungen und mehreren Zulassungen im ersten Quartal

29.04.25GlobeNewswireNovartis continues strong momentum with double-digit sales growth, robust margin expansion and multiple approvals in Q1

03.04.25PR NewswireNovartis receives FDA accelerated approval for Vanrafia® (atrasentan), the first and only selective endothelin A receptor antagonist for proteinuria reduction in primary IgA nephropathy (IgAN)

03.04.25GlobeNewswireNovartis receives FDA accelerated approval for Vanrafia® (atrasentan), the first and only selective endothelin A receptor antagonist for proteinuria reduction in primary IgA nephropathy (IgAN)

31.03.25GlobeNewswireNovartis appoints Karen Hale, Chief Legal and Compliance Officer, as Klaus Moosmayer, Chief Ethics, Risk & Compliance Officer, steps down from the Executive Committee of Novartis

28.03.25GlobeNewswireFDA approves Novartis radioligand therapy Pluvicto® for earlier use before chemotherapy in PSMA-positive metastatic castration-resistant prostate cancer

25.03.25GlobeNewswireNovartis to present new data at AAN, including seven-year disability outcomes and safety analysis of Kesimpta® in people with relapsing multiple sclerosis

21.03.25PR NewswireNovartis receives third FDA approval for oral Fabhalta® (iptacopan) - the first and only treatment approved in C3 glomerulopathy (C3G)

21.03.25GlobeNewswireNovartis receives third FDA approval for oral Fabhalta® (iptacopan) – the first and only treatment approved in C3 glomerulopathy (C3G)

19.03.25GlobeNewswireNew Novartis Phase III data demonstrate meaningful efficacy and safety results of intrathecal onasemnogene abeparvovec in broad patient population with SMA

07.03.25GlobeNewswireAktionäre von Novartis heissen an der Generalversammlung 2025 alle Anträge des Verwaltungsrats gut

07.03.25GlobeNewswireNovartis shareholders approve all resolutions proposed by the Board of Directors at the 2025 Annual General Meeting

28.02.25GlobeNewswireNovartis data presentations at AAAAI and AAD underscore commitment to advancing treatment of hidradenitis suppurativa (HS) and chronic spontaneous urticaria (CSU)

28.02.25PR NewswireNovartis data presentations at AAAAI and AAD underscore commitment to advancing treatment of hidradenitis suppurativa (HS) and chronic spontaneous urticaria (CSU)

28.02.25GlobeNewswireNovartis oral Fabhalta® (iptacopan) receives positive CHMP opinion for the treatment of adults living with C3 glomerulopathy (C3G)

20.02.25PR NewswireBMO Expands Canadian Depositary Receipt (CDR) Lineup with 10 New Listings from Europe and Japan

19.02.25PR NewswireCIBC introduces additional European Canadian Depositary Receipts ("CDRs")

11.02.25GlobeNewswireNovartis bolsters late-stage cardiovascular pipeline with agreement to acquire Anthos Therapeutics for USD 925 million upfront

31.01.25GlobeNewswireNovartis setzt die starke Umsatzdynamik mit Margenerhöhungen fort und erreicht 2024 wichtige Meilensteine bei Innovationen

31.01.25GlobeNewswireNovartis continues strong momentum of sales growth with margin expansion, reaches key innovation milestones in 2024

13.01.25GlobeNewswireNovartis Entresto® US patent upheld by US Court of Appeals

30.12.24GlobeNewswireNovartis intrathecal onasemnogene abeparvovec Phase III study meets primary endpoint in children and young adults with SMA

10.12.24GlobeNewswireLonger-term Novartis Kisqali® NATALEE data show durable reduction in distant recurrence in broad population of patients with early breast cancer

08.12.24GlobeNewswireLonger-term data for Novartis Scemblix® reinforce superior efficacy with favorable safety and tolerability profile in adults with newly diagnosed CML

06.12.24GlobeNewswireNew Phase IIIB data shows Novartis Fabhalta® improved hemoglobin levels in adult patients with paroxysmal nocturnal hemoglobinuria who switched from anti-C5 therapy

02.12.24PR NewswirePTC Therapeutics Enters into a Global License and Collaboration Agreement with Novartis for PTC518 Huntington's Disease Program

27.11.24GlobeNewswireNovartis Kisqali® receives European Commission approval in a broad population of patients with HR+/HER2- early breast cancer at high risk of recurrence

25.11.24GlobeNewswireNovartis highlights new 96-week results from Phase III Scemblix® ASC4FIRST trial at ASH and late-breaking analysis from Phase III Kisqali® NATALEE trial at SABCS

21.11.24GlobeNewswireNovartis upgrades mid-term guidance and highlights deep pipeline in core therapeutic areas to drive long-term growth

19.11.24GlobeNewswireNovartis ranks first in 2024 Access to Medicine Index

18.11.24PR NewswireRatio Enters License and Collaboration Agreement with Novartis for SSTR2-targeting Radiotherapeutic Candidate

29.10.24GlobeNewswireNovartis Scemblix® FDA approved in newly diagnosed CML, offering superior efficacy, and favorable safety and tolerability profile

29.10.24GlobeNewswireNovartis setzt die starke Dynamik im dritten Quartal fort mit Steigerungen beim Umsatz (+10%) und operativen Kernergebnis (+20%) sowie wichtigen Innovationsmeilensteinen; Prognose für 2024 angehoben

Novartis News

Novartis News: auf dieser Seite finden Sie alle Novartis News und Nachrichten zur Novartis Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Novartis News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Novartis News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.